Adiponectin normalization: a clue to the anti-metabolic syndrome action of rimonabant

Drug Discovery Today

Volumn 14, Issue 3-4, 2009, Pages 192-197

  Maynadier, Marie ^a,b,c   Basile, Ilaria ^a,b,c   Gary Bobo, Magali ^a,b,c  

^a INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^b UNIV MONTPELLIER   (France)

^c CENTRE VAL D AURELLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; RIMONABANT;

ADIPOSE TISSUE; DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; HUMAN; LIPID STORAGE; NONHUMAN; OBESITY; PROTEIN FUNCTION; REVIEW;

ADIPONECTIN; ADIPOSE TISSUE; ANIMALS; ANTI-OBESITY AGENTS; BODY FAT DISTRIBUTION; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; METABOLIC SYNDROME X; OBESITY; PIPERIDINES; PYRAZOLES;

EID: 58849113910     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2008.09.009     Document Type: Review

References (59)

1. Ogden C.L., et al. The epidemiology of obesity. Gastroenterology 132 (2007) 2087-2102
2. Isomaa B. A major health hazard: the metabolic syndrome. Life Sci. 73 (2003) 2395-2411
3. Blaha M.J., et al. A practical "ABCDE" approach to the metabolic syndrome. Mayo Clin. Proc. 83 (2008) 932-941
4. Russo A., et al. Metabolic syndrome and cancer risk. Eur. J. Cancer 44 (2008) 293-297
5. Das U.N. Is obesity an inflammatory condition?. Nutrition 17 (2001) 953-966
6. Cheung A.T., et al. An in vivo model for elucidation of the mechanism of tumor necrosis factor-alpha (TNF-alpha)-induced insulin resistance: evidence for differential regulation of insulin signaling by TNF-alpha. Endocrinology 139 (1998) 4928-4935
7. Hotamisligil G.S., et al. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 4854-4858
8. Sharma A.M., and Chetty V.T. Obesity, hypertension and insulin resistance. Acta Diabetol. 42 Suppl. 1 (2005) S3-8
9. Adiels M., et al. Fatty liver, insulin resistance, and dyslipidemia. Curr. Diab. Rep. 8 (2008) 60-64
10. Chaldakov G.N., et al. Adipobiology of disease: adipokines and adipokine-targeted pharmacology. Curr. Pharm. Des. 9 (2003) 1023-1031
11. Avram A.S., et al. Subcutaneous fat in normal and diseased states. 2. Anatomy and physiology of white and brown adipose tissue. J. Am. Acad. Dermatol. 53 (2005) 671-683
12. Hausman D.B., et al. The biology of white adipocyte proliferation. Obes. Rev. 2 (2001) 239-254
13. Trayhurn P., and Beattie J.H. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc. Nutr. Soc. 60 (2001) 329-339
14. Guerre-Millo M. Adipose tissue hormones. J. Endocrinol. Invest. 25 (2002) 855-861
15. Miner J.L. The adipocyte as an endocrine cell. J. Anim. Sci. 82 (2004) 935-941
16. Havel P.J. Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr. Opin. Lipidol. 13 (2002) 51-59
17. Spiegelman B.M., and Flier J.S. Obesity and the regulation of energy balance. Cell 104 (2001) 531-543
18. Scherer P.E., et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. Chem. 270 (1995) 26746-26749
19. Hu E., et al. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J. Biol. Chem. 271 (1996) 10697-10703
20. Maeda K., et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem. Biophys. Res. Commun. 221 (1996) 286-289
21. Nakano Y., et al. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J. Biochem. 120 (1996) 803-812
22. Lara-Castro C., et al. Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr. Opin. Lipidol. 18 (2007) 263-270
23. Ryo M., et al. Adiponectin as a biomarker of the metabolic syndrome. Circ. J. 68 (2004) 975-981
24. Trujillo M.E., and Scherer P.E. Adiponectin - journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J. Intern. Med. 257 (2005) 167-175
25. Fruebis J., et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 2005-2010
26. Berg A.H., et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat. Med. 7 (2001) 947-953
27. Yamauchi T., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7 (2001) 941-946
28. Combs T.P., et al. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J. Clin. Invest. 108 (2001) 1875-1881
29. Trayhurn P., and Wood I.S. Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochem. Soc. Trans. 33 (2005) 1078-1081
30. Ouchi N., et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 107 (2003) 671-674
31. Maeda N., et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med. 8 (2002) 731-737
32. Kubota N., et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J. Biol. Chem. 277 (2002) 25863-25866
33. Yokota T., et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96 (2000) 1723-1732
34. de Luca C., and Olefsky J.M. Inflammation and insulin resistance. FEBS Lett. 582 (2008) 97-105
35. Brunt E.M. Nonalcoholic steatohepatitis. Semin. Liver Dis. 24 (2004) 3-20
36. Bugianesi E., et al. Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship?. Dig. Liver Dis. 36 (2004) 165-173
37. Hui J.M., et al. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?. Hepatology 40 (2004) 46-54
38. Xu A., et al. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Invest. 112 (2003) 91-100
39. Masaki T., et al. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology 40 (2004) 177-184
40. Chandran M., et al. Adiponectin: more than just another fat cell hormone?. Diabetes Care 26 (2003) 2442-2450
41. Bozkurt B., and Deswal A. Obesity as a prognostic factor in chronic symptomatic heart failure. Am. Heart J. 150 (2005) 1233-1239
42. Grundy S.M. Metabolic syndrome pandemic. Arterioscler. Thromb. Vasc. Biol. 28 (2008) 629-636
43. Matsubara M., et al. Decreased plasma adiponectin concentrations in women with dyslipidemia. J. Clin. Endocrinol. Metab. 87 (2002) 2764-2769
44. Hopkins T.A., et al. Adiponectin actions in the cardiovascular system. Cardiovasc. Res. 74 (2007) 11-18
45. Imatoh T., et al. Adiponectin levels associated with the development of hypertension: a prospective study. Hypertens. Res. 31 (2008) 229-233
46. Kogan N.M., and Mechoulam R. The chemistry of endocannabinoids. J. Endocrinol. Invest. 29 (2006) 3-14
47. Pertwee R.G. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br. J. Pharmacol. 153 (2008) 199-215
48. Cota D., et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J. Clin. Invest. 112 (2003) 423-431
49. Di Marzo V., et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410 (2001) 822-825
50. Bensaid M., et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol. Pharmacol. 63 (2003) 908-914
51. Van Gaal L., et al. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 31 Suppl. 2 (2008) S229-240
52. Gary-Bobo M., et al. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol. Pharmacol. 69 (2006) 471-478
53. Gary-Bobo M., et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 46 (2007) 122-129
54. Tilg H., and Diehl A.M. Cytokines in alcoholic and nonalcoholic steatohepatitis. N. Engl. J. Med. 343 (2000) 1467-1476
55. Dandona P., et al. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 25 (2004) 4-7
56. Teixeira-Clerc F., et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat. Med. 12 (2006) 671-676
57. Osei-Hyiaman D., et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J. Clin. Invest. 115 (2005) 1298-1305
58. Despres J.P., et al. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 353 (2005) 2121-2134
59. Despres J.P., et al. Efficacy and safety of the weight-loss drug rimonabant. Lancet 371 (2008) 555 author reply 556-557